GTHP · Guided Therapeutics Inc
$0.21
-0.02 (-6.67%)
At close · Sep 1
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The factors below raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.72M
Shares
96.54M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.21
Open$0.21
Day$0.21–0.21
52W close$0.16–0.54
Avg vol 30d12K
Short int3K · 0.0% float · 1.0d
Short vol100%
DataJan 2021–Sep 2026
Filing10-Q · Aug 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
−17%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
13%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−46%
trailing
YTD return
−61%
this year
Relative strength
−59%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +113.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Squeeze score
27
low risk · 0–100
Fundamentals
Revenue growth
+10857%
Y/Y
Gross margin
74%
expanding
EPS growth
+20%
Y/Y
Free cash flow
$-1.1M
Balance sheet
$621.0K
net cash
Quant / Vol
risk profile
Volatility
187%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
12.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
−17%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
13%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +113.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 13%
Range high $1
vs 200-day avg -25%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GTHP
this stock
Guided Therapeutics Inc
|
$21.72M | -61.1% | +10857.1% | — | 0.0% |
|
ABT
Abbott Laboratories
|
$191.81B | -13.1% | +5.7% | 30.9 | 1.2% |
|
SYK
Stryker Corp
|
$126.84B | -9.7% | +11.2% | 34.3 | 1.8% |
|
MDT
Medtronic plc
|
$116.78B | -4.2% | +8.4% | 24.5 | 1.1% |
|
BSX
Boston Scientific Corp
|
$70.00B | -49.6% | +12.5% | 19.6 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
1
- % held
- 0.0%
- Net QoQ
- -1 sh
- Top holder
- Steward Partners Investme…
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GTHP | -16.0% | -19.2% | -46.2% | -6.7% | -61.1% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -15.5% | -18.0% | -58.8% | -6.0% | -72.8% |